MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Related Questions
Are there any regulatory or clinical trial milestones mentioned that could drive future price movements?
Did management provide any forward guidance or updates on the pipeline that could affect future revenue?
Did the webcast reveal any strategic partnerships, licensing deals, or M&A activity that could impact valuation?
What were the actual Q2 2025 financial results compared to analyst expectations?
What is the expected impact of the Q2 results on institutional and retail ownership trends for CELC?
What is the market's perception of CELC's recent clinical trial outcomes and how does this influence investor sentiment?
Are there any notable changes in operating expenses or cash burn that could affect the company's runway?
How might the Q2 results impact CELC's short-term stock price volatility?
How might the Q2 earnings release influence the technical chart patterns and trading volume for CELC moving forward?
How does CELC's Q2 performance compare to its direct competitors in the oncology biotech space?